ESR1 and breast cancer: These results suggest that dysfunction of the regulatory mechanisms governing ERα genomic binding contribute to the development of endocrine‐resistant ER+ breast cancer, and we hypothesized that chromatin remodeling enzymes that can regulate the ERα genomic landscape may contribute to endocrine resistance.